Prevail Therapeutics Inc.
https://www.prevailtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Prevail Therapeutics Inc.
Allo CAR-T Is Still On The Shelf As Precision Moves On
Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice